Trial Profile
Induction Gemcitabine/Capecitabine Followed by SBRT in Pancreatic Adenocarcinoma A Prospective Evaluation in Patients With Locally Advanced Pancreas Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Mar 2022
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Gemcitabine (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 12 Apr 2021 Status changed from active, no longer recruiting to completed.
- 17 Jan 2020 Planned primary completion date changed from 1 Dec 2019 to 1 May 2020.
- 08 Jan 2019 Planned End Date changed from 1 Jun 2019 to 1 Jun 2020.